埃他卡林对压力超负荷大鼠心室重构和血浆中PGI2的影响

目的：观察埃他卡林（IPT）对压力超负荷大鼠心室重构的影响,探讨其保护作用与血浆中前列环素（PGI2）的关系。方法：SD大鼠经腹主动脉缩窄6周后诱导压力超负荷高血压模型,随机分为5组（n=9）：①假手术组;②模型组;③IPT 3mg／kg组（IPT 3）;④吲哚美辛2mg/kg（Indo2）组;⑤IPT 3mg／kg＋吲哚美辛2mg／kg（IPT 3＋Indo2）组。RM-6000八导生理记录仪记录血流动力学改变,称量计算心脏重量指数,HE染色和iassort’s染色观察心肌组织病理学改变,比色法检测心肌组织羟脯氨酸含量,放免法检测血浆中PGI2含量。结果：腹主动脉缩窄6周后,与假手术组相比,模型组大鼠出现了明显的高血流动力学状态和心室重构,血浆中PGI2含量也明显降低。而IPT 3mg／kg实验治疗6周可明显改善上述变化。单用吲哚美辛可进一步恶化大鼠的高血流动力学状态和心室重构,合用肼可明显改善高血流动力学状态和心肌纤维化,明显抑制血浆中PGI2含量的降低。结论：IPT可明显逆转腹主动脉缩窄／压力超负荷大鼠的心室重构,其机制可能与胛作用于内皮细胞上的KATP通道,恢复内皮细胞的分泌功能增加PGI2的合成和分泌密切相关。     

人参皂苷Rg2对异丙肾上腺素诱导的大鼠心室重构的保护作用

目的：探讨人参皂苷Rg2对异丙肾上腺素诱导的心室重构模型大鼠的保护作用。方法：将60只雄性Wistar大鼠随机分为对照组、心室重构模型组、人参皂苷Rg2（20、40、80 mg/kg）组和普萘洛尔（propranolol,15 mg/kg）组,n=10。采用多点皮下注射异丙肾上腺素85 mg/（kg·d）,连续7 d,建立大鼠心室重构模型;对照组皮下注射等体积的生理盐水。此后按分组灌胃给药,每天1次,连续给药6 w后,使用八道生理记录仪测定血流动力学参数,并测定心脏重量和左心室重构指数。结果：与对照组相比,注射异丙肾上腺素后第7周时模型组大鼠颈动脉收缩压、舒张压、平均动脉压、心率、LVSP、+dp/dt_max、-dp/dt_max显著降低（P<0.01）;而HW/BW和LVW/BW、LVDP显著升高（P<0.01）。与模型组相比,人参皂苷Rg2低、中、高剂量组和普萘洛尔组大鼠颈动脉收缩压、舒张压、平均动脉压、心率、LVSP、+dp/dt_max、-dp/dt_max显著升高（P<0.05,P<0.01）;LVDP显著降低（P<0.01）,而人参皂苷Rg2中、高剂量组和普萘洛尔组大鼠HW/BW和LVW/BW显著降低（P<0.01）。与普萘洛尔组相比,人参皂苷Rg2低剂量组收缩压、舒张压、平均动脉压显著降低（P<0.05,P<0.01）;人参皂苷Rg2低剂量组LVDP和高剂量组LVSP和+dp/dt_max显著升高（P<0.05,P<0.01）。结论：人参皂苷Rg2对异丙肾上腺素所致的心室重构模型大鼠具有改善作用。     

乳酸左氧氟沙星对豚鼠心肌细胞电生理的影响

目的了解乳酸左氧氟沙星(LVFX)对豚鼠心室肌细胞电生理的影响.方法经腹腔注射不同剂量的LVFX,记录并分析注药后5～360 min豚鼠Ⅱ导联心电图的QT间期,以及校正的QT间期(QTc).采用全细胞膜片钳技术,记录不同浓度LVFX对体外单个心室肌细胞的延迟整流钾电流(IK)的作用.结果①LVFX给药量为200 mg/kg时,心电图QT间期延长19.38%±3.15%(P＜0.05);在50 mg/kg和100 mg/kg等较低剂量时,QT间期延长不明显(P＞0.05).②LVFX抑制IK电流,且抑制作用呈现电压依赖性和浓度依赖性.结论LVFX可能通过抑制心肌细胞IK电流引起心脏QT间期延长,临床应谨慎使用.     

氟烷对慢性缺氧兔心肌β肾上腺素能受体的影响

用放射配基结合法和高效液相色谱电化学法分别测定氟烷对慢性缺氧免心肌β肾上腺素能受体（简称β受体）和血浆儿茶酚胺的影响。结果表明：慢性缺氧后兔心肌β受体密度明显下降,受体亲和力无明显变化,血浆肾上腺素、去甲肾上腺素明显升高。缺氧吸入氟烷后兔心肌β受体密度进一步下降,亲和力增加,血浆肾上腺素、去甲肾上腺素无进一步变化。常氧吸入氟烷后心肌β受体密度无明显变化,亲和力升高,血浆肾上腺素、去甲肾上腺素反而降低。结果提示,氟烷抑制常氧兔交感神经活动而不能抑制缺氧兔交感神经活动,氟烷不改变常氧兔心肌β受体密度,但降低缺氧兔心肌β受体密度。β受体密度降低与缺氧后升高的儿茶酚胺下调β受体数目有关,同时可能与氟烷改变了缺氧心肌细胞膜脂质流动性使受体易向膜内移动有关。     

有氧康复运动对慢性心力衰竭患者心室重构及血管内皮功能的影响

目的:探讨有氧康复运动对慢性心力衰竭(chronic cardiac failure,CHF)患者心室重构及血管内皮功能的影响。方法:78例CHF患者随机分为运动组(n=39)、对照组(n=39)。对照组给予常规内科药物治疗、日常活动能力训练,运动组在此基础上根据美国心脏病学会(American Heart Association,AHA)的《三阶段康复运动方案》进行有氧康复运动,共持续12周。比较两组治疗前后心脏结构和功能、血管内皮功能及生活质量的改善情况。结果:干预后,两组左室收缩末期内径(left ventricular end systolic diameter,LVESD)、左室舒张末期内径(left ventricular end-diastolic diameter,LVEDD)、明尼苏达心衰生活质量(Minnesota Living With Heart Failure,MLHF)评分、血清内皮素-1(Endothelin-1,ET-1)、血管紧张素Ⅱ(angiotensin Ⅱ,Ang Ⅱ)水平均明显减小,左室射血分数(left ventricular ejection fraction,LVEF)、6分钟步行试验(6 minute walking test,6MWT)、血清一氧化氮(nitric oxide,NO)、降钙素基因相关肽(calcitonin gene-related peptide,CGRP)水平均明显升高,且运动组LVESD、LVEDD、MLHF评分、血清ET-1、Ang Ⅱ水平明显低于对照组,LVEF、6MWT、血清NO、CGRP水平明显高于对照组,差异均有统计学意义(P0.05)。运动组干预期间心衰再入院率显著低于对照组,差异均有统计学意义(P0.05)。结论:有氧运动康复训练有助于改善CHF患者的血管内皮功能,延缓或逆转心室重构,提高生活质量,改善预后。     

左西孟旦联合螺内酯对慢性心力衰竭患者血清炎症因子水平及心室重构的影响研究

目的:研究左西孟旦联合螺内酯对慢性心力衰竭患者血清炎症因子水平及心室重构的影响。方法:选择2015年1月-2017年12月我院干部病房收治的88例慢性心力衰竭患者,将其随机分为两组。对照组单纯口服螺内酯,每次20 mg,每天1次;观察组联合采取左西孟旦治疗。观察和比较两组治疗前后的心功能指标(左心室舒张期末内径、6 min步行试验、左心室射血分数以及左心室收缩期末内径),血清肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)、白介素-6 (interleukin-6,IL-6)、高敏C-反应蛋白(high sensitivity C-reactive protein,hs-CRP)、N端脑钠肽前体(N-terminal pro-brain natriuretic peptide,NT-proBNP)水平的变化情况。结果:治疗后,观察组的有效率明显高于对照组(90.91%vs. 72.73%,P0.05);两组治疗后左心室舒张期末内径、左心室收缩期末内径、血清hs-CRP、TNF-α、IL-6和NT-proBNP水平均较治疗前显著降低,而左心室射血分数及6 min步行试验均较治疗前明显增加(P0.05),且观察组左心室舒张期末内径、左心室收缩期末内径、血清hs-CRP、TNF-α、IL-6和NT-proBNP水平明显低于对照组,左心室射血分数及6 min步行试验显著高于对照组(P0.05)。结论:左西孟旦联合螺内酯治疗慢性心力衰竭患者可能显著提高其临床疗效,可能与其有效改善患者的心功能以及心室重构、减轻机体炎症反应有关。     

慢性心力衰竭患者外周血miR-148a表达水平与炎症因子、心功能和心室重构的关系

摘要 目的：探讨慢性心力衰竭（CHF）患者血清miR-148a表达水平与炎症因子、心功能和心室重构的关系。方法：选择2017年1月~2019年1月在我院就诊的CHF患者136例,按照美国纽约心脏病学会（NYHA）心功能分级将患者分为Ⅱ级57例、Ⅲ级43例和Ⅳ级36例。实时荧光定量PCR检测血清miR-148a的表达,血清中白细胞介素-1（IL-1）、白细胞介素6（IL-6）和肿瘤坏死因子-α（TNF-α）的含量用酶联免疫吸附试验检测,使用超声心动图检测心功能和心室重构指标,主要包括左室舒张末期内径（LVEDD）、舒张末室间隔厚度（IVSD）、舒张末左室后壁厚度（PWD）、左室质量指数（LVMI）、左室射血分数（LVEF）和左室重构指数（LVRI）,采用Pearson积矩相关系数分析血清miR-148a表达水平与血清炎症因子、超声心动图指标之间的相关性。结果：CHF患者血清miR-148a表达量随心功能分级升高而降低（P均<0.05）。炎症因子（IL-1、IL-6和TNF-α）水平和LVEDD、PWD、IVSD、LVMI随心功能分级升高而升高, LVRI和LVEF随心功能分级升高而降低（P<0.05）。血清miR-148a表达量与炎症因子、IVSD、PWD和LVMI呈负相关（P<0.05）;与LVEF和LVRI呈正相关（P<0.05）。结论：血清miR-148a表达量与CHF患者血清炎症因子水平、心功能及心室重构关系密切,提示检测血清miR-148a有助于反映CHF患者病情的严重程度。     

沙库巴曲缬沙坦调控RhoA/ROCK信号通路对慢性心力衰竭心室重构的影响研究

摘要 目的：分析沙库巴曲缬沙坦对慢性心力衰竭（CHF）动物模型RhoA/ROCK信号通路的调控以及对心室重构的影响效应。方法：将45只SD大鼠随机分成3组：空白组（予以生理盐水）、模型组（予以阿霉素腹腔注射制备CHF大鼠模型）和治疗组（予以CHF大鼠60 mg/kg沙库巴曲缬沙坦灌胃4周),每组15只。比较3组大鼠左心室射血分数（LVEF）、左心室舒张末期内径（LVEDD）、室间隔厚度（IVST）、左心室心肌质量指数（LVMI）等心脏结构指标以及血浆N末端脑钠肽前体（NT-proBNP）、基质金属蛋白酶9（MMP-9）、半乳糖凝集素3（Gal-3）水平。比较3组大鼠心肌组织形态学以及心肌胶原沉积程度。比较3组大鼠心肌组织RhoA及ROCK mRNA以及蛋白表达水平差异。结果：空白组大鼠LVEF最高,且治疗组大于模型组（P<0.05）;空白组大鼠LVEDD、IVST、LVMI最低,且治疗组小于模型组（P<0.05）。空白组大鼠NT-proBNP、MMP-9及Gal-3最高,且治疗组大于模型组（P<0.05）。模型组心肌细胞增大,排列紊乱,心肌胶原沉积显著大于治疗组。空白组大鼠RhoA及Rock mRNA及蛋白水平最低,且治疗组低于模型组（P<0.05）。模型组及治疗组大鼠RhoA及Rock mRNA以及蛋白的表达与LVEDD、IVST、LVMI、NT-proBNP、MMP-9及Gal-3呈正相关,与LVEF呈负相关（P<0.05）。结论：沙库巴曲缬沙坦通过靶向负调控RhoA/ROCK信号通路影响CHF心室重构程度。     

Effect of simvastatin on remodeling of the left ventricle and aorta in L-NAME-induced hypertension

3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors have been shown to prevent or reverse hypertrophy of the LV in several models of left ventricular hypertrophy. The aim of the present study was to determine whether treatment with simvastatin can prevent hypertension, reduction of tissue nitric oxide synthase activity and left ventricular (LV) remodeling in NG-nitro-L-arginine methyl ester(L-NAME)-induced hypertension. Four groups of rats were investigated: control, simvastatin (10 mg/kg), L-NAME (40 mg/kg) and L-NAME + simvastatin (in corresponding doses). Animals were sacrificed and studied after 6 weeks of treatment. The decrease of NO-synthase activity in the LV, kidney and brain was associated with hypertension, LV hypertrophy and fibrosis development and remodeling of the aorta in the L-NAME group. Simvastatin attenuated the inhibition of NO-synthase activity in kidney and brain, partly prevented hypertension development and reduced the concentration of coenzyme Q in the LV. Nevertheless, myocardial hypertrophy, fibrosis and enhancement of DNA concentration in the LV, and remodeling of the aorta were not prevented by simultaneous simvastatin treatment in the L-NAME treated animals.We conclude that the HMG-CoA reductase inhibitor simvastatin improved nitric oxide production and partially prevented hypertension development, without preventing remodeling of the left ventricle and aorta in NO-deficient hypertension.     

一种改进的人体心房肌细胞分离方法

本研究旨在探讨稳定的人体心房肌细胞分离方法,并观察分离的正常窦性心律（normal sinus rhythm,NSR）患者右心房肌细胞基本电生理特性。XXIV型蛋白酶和V型胶原酶两步法进行单个人体心房肌细胞分离,常规全细胞膜片钳技术记录正常的L-型钙通道电流（L-type calcium current,ICa-L）、钠通道电流（sodiumcurrent,INa）、瞬时外向钾通道电流（transient outward potassium current,Itol）和内向整流钾通道电流（inward rectifier potassium current,Ik1）。此方法分离的人体心房肌细胞数量多,细胞膜光滑,折光性强,横纹清楚,耐钙,可用于膜片钳实验的占分离细胞总数的50％-60％。该方法简单、稳定、可靠,酶用量少,分离的心肌细胞质量好,数量多,并能记录到多种离子通道电流,表明其具有正常的电生理功能,适合膜片钳实验。     

Association of increased oncostatin M with adverse left ventricular remodeling in patients with myocardial infarction

BackgroundThe study of laboratory biomarkers that reflect the development of adverse cardiovascular events in the postinfarction period is of current relevance. The aim of the present study was evaluation of oncostatin M (OSM) concentration changes in the early and late stages of myocardial infarction and evaluation of the possibility of its use in prediction of adverse left ventricular (LV) remodeling in patients with myocardial infarction with ST-elevated segment (STEMI).MethodsThe study involved 31 patients with STEMI admitted in the first 24 hours after the onset of MI and 30 patients with chronic coronary artery disease as a control group. Echocardiographic study was performed on day 3 and in 6 months after STEMI. The serum levels of biomarkers were evaluated on the day of hospital admission and 6 months after MI using multiplex immunoassay.ResultsOSM level increased during the first 24 h after the onset of the disease, with the following decrease in 6 months. OSM concentration at admission had correlated with echocardiography parameters and Nt-proBNP, troponin I, CK-MB levels. Our study has demonstrated association of the increased levels of OSM at the early stages of STEMI with development of the adverse LV remodeling in 6 months after the event.ConclusionsElevation of OSM levels in the first 24 h after STEMI is associated with the development of the adverse LV remodeling in the long-term post-infarction period.     

Changes of collagen metabolism predict the left ventricular remodeling after myocardial infarction

Objectives: To analyze the predictive value of cardiac collagen metabolism “in vivo" in patients with myocardial infarction (MI) treated with percutaneous coronary intervention (PCI). Design: Forty-five patients (age 66 ± 8.27) underwent biochemical analysis for cardiac collagen metabolism (groups A, B and C); 30 patients with their first MI were treated with successful PCI (group A; n = 30), group B (n = 5) were MI patients with unsuccessful PCI. Group C were patients without MI (n = 10), they underwent elective diagnostic coronary angiography only. The collagen metabolism was analyzed in acute and subacute MI phases by using serum blood markers: the carboxy-terminal propeptide of type I procollagen (PICP), amino-terminal propeptide of type III procollagen (PIIINP) and carboxy-terminal telopeptide of type I collagen (ICTP). Furthermore, the ejection fraction (EF) and left ventricular end-diastolic volume maximal changes in the course of 6 months were measured by echocardiography. Results: A significant increase of both PICP and PIIINP on day 4 following MI was detected. Furthermore, PICP and PIIINP level assessed on the 30th day was significantly higher in the PCI unsuccessful group versus successful group. PICP level on day 4 above 110 ug/l and PIIINP level above 4 ug/l was significantly often found in the subgroup of patients with the EF improvement less than 10% or worsening and with significant left ventricular dilatation during 6 months follow-up. Cardiac catheterization itself does not affect collagen metabolism. Conclusion: We concluded that collagen metabolism markers enable to study in vivo the MI healing and to predict left ventricular functional and volume changes.     

AT2 receptor mediates the cardioprotective effects of AT1 receptor antagonist in post-myocardial infarction remodeling

There are two subtypes of angiotensin (Ang) II receptors, AT1R and AT2R. It is established that clinical use of specific AT1R blocker (ARB) improves the long-term prognosis of heart failure. However, scientific basis for such effects of ARB is incompletely understood. The present study was designed to determine whether ARB inhibits the left ventricular (LV) remodeling that occurs early after myocardial infarction (MI) and whether the benefit of ARB is mediated by blockade of AT1R itself or by stimulation of AT2R resulting from AT1R blockade. MI was induced in AT2R-knockout mice and wild-type mice. Administration of valsartan, an ARB, or vehicle was started soon after the surgery and continued for two weeks. Infarction caused significant increase in end diastolic and end systolic LV dimensions, LV/body weight ratio, and myocyte cross-sectional area (MCSA) in both strains to a similar extent. Lung/body weight ratio, an index of pulmonary congestion, was also significantly increased in both strains, but the magnitude of increase was significantly larger in knockout mice. Valsartan significantly reduced LV dimensions, LV/body weight ratio, MCSA, and lung/body weight ratio in wild-type mice. In knockout mice, however, valsartan failed to inhibit the increases in LV dimensions and LV/body weight ratio. After the treatment, lung/body weight ratio in the mutant strain was significantly larger than that in the wild-type mice. Valsartan attenuates acute phase post-infarction remodeling and ameliorates heart failure, and a large part of its cardioprotective effect was mediated by AT2R.     

Effects of Angiotensin II type I receptor shRNA on blood pressure and left ventricular remodeling in spontaneously hypertensive rats

This study was designed to investigate the effects of the Angiotensin II type I receptor (AT1R) shRNA on blood pressure and left ventricular remodeling in spontaneously hypertensive rats. Ten Wistar Kyoto (WKY) rats were used as a normal blood pressure control group, and 20 spontaneously hypertensive rats (SHR) were randomly divided into the experimental and hypertension control groups. The rats in the experimental group were injected with AT1R shRNA recombinant adenovirus (Ad5-AT1R-shRNA) via a tail vein, and the rats in the other two groups were injected with recombinant adenovirus (Ad5-EGFP). The systolic blood pressure (SBP) at rat arteria caudalis was measured before and after the injection, and the heart, kidney, aorta, and adrenal tissues were obtained two days after repeated injection to observe the distribution of Ad5-AT1R-shRNA under a fluorescence microscope. Before the injection of Ad5-AT1R-shRNA, the blood pressure of the experimental group and the hypertension control group was significantly higher than that of the normal blood pressure control group (P<0.01). After two injections, the blood pressure in the experimental group decreased significantly, and the duration of blood pressure reduction reached 19 days. In the experimental group, the kidney, heart, aorta, and adrenal gland tissues showed vigorous fluorescence expression under the fluorescence microscope. Repeated administration of Ad5-AT1R-shRNA has a long-lasting hypotensive effect on SHR and can significantly improve ventricular remodeling.     

Diverse effects of long-term treatment with imidapril and irbesartan on cell growth signal, apoptosis and collagen type I expression in the left ventricle of spontaneously hypertensive rats

To compare diverse effects of angiotensin II type 1 receptor antagonists (irbesartan) and angiotensin converting enzyme inhibitors (imidapril) on left ventricular remodeling in spontaneously hypertensive rats (SHR). Thirty male SHR were randomly divided into three groups: SHR-IR (treated with irbesartan, 50 mg/kg), SHR-IM (imidapril, 3 mg/kg), SHR-C (placebo). Ten male Wistar Kyoto rats (WKY) treated with placebo acted as the control. All treatments were administered once daily from 14 to 27 weeks of age. Imidapril and irbesartan have the similar inhibitor effects on blood pressure and left ventricular mass indexes in SHR. Despite both drugs suppressed ERK-1 protein expression, decreased cardiomyocytes apoptosis index, blocked collagen type I deposition, reduced TGF-beta(1) gene expression in SHR, imidapril elicits a stronger inhibitory effect. Irbesartan had little effect on MKP-1 protein expression, but imidapril decreased it significantly. As a result, the ERK-1/MKP-1 ratio in SHR-IR was significantly greater than that in SHR-IM (P < 0.05). These results suggest that the balance between MKP-1 and ERKs in myocardial tissue is important for cardiac cell proliferation and growth. They also indicate that the similar efficacy of antihypertensive treatment in reducing blood pressure does not predict the similar capacity to control the individual facet of left ventricular remodeling. Irbesartan is more effective in regressing the homeostasis between ERK-1 and MKP-1, however imidapril is superior in suppressing apoptosis and collagen synthesis in cardiac tissue.     

Role of cardiac renin-angiotensin system in the development of pressure-overload left ventricular hypertrophy in rats with abdominal aortic constriction

Possible involvement of cardiac renin-angiotensin system (RAS) in pressure overload induced left ventricular hypertrophy (LVH) was investigated. Rats were subjected to abdominal aortic constriction (AAC) and examined the effects of 4 weeks treatments with an angiotensin converting enzyme (ACE) inhibitor, captopril and a vasodilator, hydralazine on haemodynamics and ventricular RNA, DNA, protein and myosin isoform pattern in sham and hypertrophied rats. AAC increased the mean arterial pressure (MAP) and systolic blood pressure (SBP), and resulted in increased left ventricle/body weight ratio, LV thickness, RNA and protein content, however total DNA was not changed. The expression of fetal isogene, -myosin heavy chain (-MHC), was markedly enhanced where as u.-MHC was reduced. High-dose captopril (100 mg/kg p.o.,) significantly prevented the increase in haemodynamics, development of LVH, LV remodeling, increase in total protein, RNA and antithetical expression of myosin isoforms. Hydralazine (15 mg/kg p.o.,), did not modulate hypertrophic changes and low-dose captopril (1.5 mg/kg p.o.,) which has not produced any marked fall in MAP and SBP also modulated favourably the development of LVH and its biochemical markers. Thus, the prevention of the development of LVH and induction of -MHC by non-hypotensive doses of captopril may be related to the blockade of intracardiac production of angiotensin II rather than circulating system. These results suggest that cardiac RAS may play an important role in pressure overload induced LVH.     

Functional suppression of Epiregulin impairs angiogenesis and aggravates left ventricular remodeling by disrupting the extracellular-signal-regulated kinase1/2 signaling pathway in rats after acute myocardial infarction

Acute myocardial infarction (AMI), a severe consequence of coronary atherosclerotic heart disease, is often associated with high mortality and morbidity. Emerging evidence have shown that the inhibition of the extracellular-signal-regulated kinase (ERK) signaling pathway appears to protect against AMI. Epiregulin (EREG) is an autocrine growth factor that is believed to activate the MEK/ERK signaling pathway. Therefore, the aim of the present study was to determine the expression patterns of EREG in AMI and to further study its effects on AMI induced experimentally in rats focusing on angiogenesis and left ventricular remodeling. Microarray-based gene expression profiling of AMI was used to identify differentially expressed genes. To understand the biological significance of EREG and whether it is involved in AMI disease through the ERK1/2 signaling pathway, rats after AMI were treated with small interfering RNA (siRNA) against EREG, an ERK1/2 pathway inhibitor, PD98059, or both of them. The microarray data sets GSE66360 and GSE46395 showed that EREG was robustly induced in AMI. Both siRNA-mediated depletion of EREG and PD98059 treatment were shown to significantly increase infarct size and left ventricular cardiomyocyte loss and enhance left ventricular remodeling. In addition, we also found that the ERK1/2 signaling pathway was inhibited following siRNA-mediated EREG inhibition and PD98059 could enhance the effects of EREG inhibition on AMI. In conclusion, these findings highlight that the silencing of EREG inhibits angiogenesis and promotes left ventricular remodeling by disrupting the ERK1/2 signaling pathway, providing a novel therapeutic target for limiting AMI.